Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Eli Lilly
WIPO
Eli Lilly
WIPO
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [G810S](Homo sapiens (Human))
Eli Lilly
WIPO
Eli Lilly
WIPO
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Eli Lilly
WIPO
Eli Lilly
WIPO
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [G810S](Homo sapiens (Human))
Eli Lilly
WIPO
Eli Lilly
WIPO
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Eli Lilly
WIPO
Eli Lilly
WIPO
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [G810S](Homo sapiens (Human))
Eli Lilly
WIPO
Eli Lilly
WIPO
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Eli Lilly
WIPO
Eli Lilly
WIPO
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [G810S](Homo sapiens (Human))
Eli Lilly
WIPO
Eli Lilly
WIPO
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Eli Lilly
WIPO
Eli Lilly
WIPO
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [G810S](Homo sapiens (Human))
Eli Lilly
WIPO
Eli Lilly
WIPO
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Eli Lilly
WIPO
Eli Lilly
WIPO
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [G810S](Homo sapiens (Human))
Eli Lilly
WIPO
Eli Lilly
WIPO
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Eli Lilly
WIPO
Eli Lilly
WIPO
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [G810S](Homo sapiens (Human))
Eli Lilly
WIPO
Eli Lilly
WIPO
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Eli Lilly
WIPO
Eli Lilly
WIPO
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [G810S](Homo sapiens (Human))
Eli Lilly
WIPO
Eli Lilly
WIPO
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Eli Lilly
WIPO
Eli Lilly
WIPO
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [G810S](Homo sapiens (Human))
Eli Lilly
WIPO
Eli Lilly
WIPO
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Eli Lilly
WIPO
Eli Lilly
WIPO
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [G810S](Homo sapiens (Human))
Eli Lilly
WIPO
Eli Lilly
WIPO
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Eli Lilly
WIPO
Eli Lilly
WIPO
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [G810S](Homo sapiens (Human))
Eli Lilly
WIPO
Eli Lilly
WIPO
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Eli Lilly
WIPO
Eli Lilly
WIPO
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [G810S](Homo sapiens (Human))
Eli Lilly
WIPO
Eli Lilly
WIPO
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Eli Lilly
WIPO
Eli Lilly
WIPO
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [G810S](Homo sapiens (Human))
Eli Lilly
WIPO
Eli Lilly
WIPO
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Eli Lilly
WIPO
Eli Lilly
WIPO
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [G810S](Homo sapiens (Human))
Eli Lilly
WIPO
Eli Lilly
WIPO
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Eli Lilly
WIPO
Eli Lilly
WIPO
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [G810S](Homo sapiens (Human))
Eli Lilly
WIPO
Eli Lilly
WIPO
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Eli Lilly
WIPO
Eli Lilly
WIPO
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [G810S](Homo sapiens (Human))
Eli Lilly
WIPO
Eli Lilly
WIPO
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair
TargetProto-oncogene tyrosine-protein kinase receptor Ret [V804M](Homo sapiens (Human))
Eli Lilly
WIPO
Eli Lilly
WIPO
Affinity DataIC50: <150nMAssay Description:Compounds of formulas I, la to lx, Ila to IIx, and/or Illa to IIIx are screened for their ability to inhibit wildtype, V804M, and G810S mutant RET ki...More data for this Ligand-Target Pair